STORM Therapeutics was founded in 2015 by two Cambridge researchers, following their ground-breaking work in RNA epigenetics.
They identified the importance of RNA modifications during the development of cancer, creating the pathway for STORM to develop pioneering cancer drugs targeting this new mechanism.
STORM‘s leadership team is dedicated to advancing its first-in-class pipeline into other areas as well as cancer, including inflammation and neurodegenerative and infectious diseases.
Its lead product, STC-15, is the first RNA modifying enzyme inhibitor to enter human clinical trials, currently being evaluated in a Phase 1 study in patients with advanced solid tumours.
"The work that our research groups are undertaking on non-coding RNA and the enzymes that modify this RNA is giving us incredibly interesting insights into how gene expression can be modified at a cellular level."
Pioneering RNA-targeted cancer therapies
STORM Therapeutics, founded in 2015, is a drug discovery and development company that emerged from the University of Cambridge’s Gurdon Institute. The company focuses on targeting enzymes that modify RNA using small molecules, aiming to develop first-in-class targeted therapies for cancers with unmet needs. The foundational work of Professors Tony Kouzarides and Eric Miska in RNA epigenetics underpins Storm Therapeutics’ innovative approach to cancer treatment.
In 2016, STORM Therapeutics secured £12 million in Series A funding from prominent investors including Cambridge Innovation Capital, Imperial Innovations, Merck Ventures, and Pfizer Venture Investments. This investment will support the development of small molecule modulators targeting RNA modification pathways, with the goal of advancing these novel therapeutics into clinical trials. The company continues to leverage its groundbreaking research to explore new therapeutic targets and expand its pipeline of potential cancer treatments.
